Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib


Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, ss.281-289, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 24 Konu: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1177/1078155217697486
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Sayfa Sayısı: ss.281-289

Özet

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.